Please assess the completion status of the following clinical trial:

Trial Title: Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion criteria:~* A male or female between, and including, 6 and 12 weeks (42-90 days) of age at the time of the first vaccination.~* Written informed consent obtained from the parent or guardian of the subject.~* Free of obvious health problems as established by medical history and clinical examination before entering into the study.~* Vaccinated against hepatitis B at birth.~* Born after a gestation period of 36 - 42 weeks.~Exclusion criteria:~* Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* Chronic administration of immunosuppressants or other immune-modifying drugs since birth~* Any chronic drug therapy to be continued during the study period.~* Planned administration/ administration of a vaccine not foreseen by the study protocol within one month of the first dose of vaccine(s).~* Previous vaccination against diphtheria, tetanus, pertussis, polio, N. meningitidis of serogroups C and Y, Haemophilus influenzae type b or Streptococcus pneumoniae.~* History of or known exposure to diphtheria, tetanus, pertussis, polio, or invasive diseases due to N. meningitidis of serogroups C and Y, Haemophilus influenzae type b or Streptococcus pneumoniae.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.~* A family history of congenital or hereditary immunodeficiency.~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.~* Major congenital defects or serious chronic illness.~* History of any neurologic disorders or seizures.~* Acute disease at the time of enrolment.~* Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 12 Weeks
- Healthy Volunteers: t

Study Arms:
- MenHibrix Formulation 1 Group (Type: EXPERIMENTAL): Subjects were primed with MenHibrix formulation 1 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.
- MenHibrix Formulation 2 Group (Type: EXPERIMENTAL): Subjects were primed with MenHibrix formulation 2 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.
- MenHibrix Formulation 3 Group (Type: EXPERIMENTAL): Subjects were primed with MenHibrix formulation 3 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.
- Menjugate Group (Type: ACTIVE_COMPARATOR): Subjects were primed with Menjugate co-administered with Infanrix Penta and ActiHIB according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.
- ActHIB Group (Type: ACTIVE_COMPARATOR): Subjects were primed with ActHIB co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).